A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma

Trial Profile

A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECTIONS
  • Sponsors Pfizer
  • Most Recent Events

    • 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Jan 2018 According to a Pfizer media release, results of the study will be presented at a future medical meeting or summarized in publication.
    • 24 Jan 2018 Primary endpoint has been met. (Objective Response Rate (ORR) according to the revised response criteria for malignant lymphoma), according to a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top